HSBC Continental Europe announced that no price stabilisation activities were undertaken by the stabilisation manager for Sanofi's bond offerings in 2026. The bonds, with fixed rates maturing in 2029, 2033, and 2037, were offered at prices just below par. This notice informs investors that the bond prices were not artificially supported post-offer, reflecting natural market conditions. It is a routine disclosure following bond issuance to maintain transparency.
HR Tech 2026, scheduled for October 20-22 in Las Vegas, announced its agenda centered on real-world AI implementation, workforce skills, and HR transformation. The event features sessions from leaders at major companies like IFF, Lumen, and Sanofi, c...
Kymera Therapeutics has dosed the first participant in the Phase 1 clinical trial of KT-485, an oral IRAK4 degrader, marking a key milestone under its collaboration with Sanofi. This event triggered a $20 million milestone payment from Sanofi to Kyme...
